A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of BupiVacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal

Status: Completed
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospitalization costs.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: No
View:

• Male or female, 18 years of age and older

• Patients scheduled to undergo ileostomy reversal

• Ability to provide informed consent, adhere to study visit schedule, and complete all assessments.

Locations
United States
Arizona
University of Arizona College of Medicine
Tucson
Florida
Florida Hospital d/b/a Colon & Rectal Surgery Center
Orlando
University of South Florida
Tampa
Time Frame
Start Date: January 2012
Completion Date: October 2012
Participants
Target number of participants: 33
Treatments
Active Comparator: Group 1
IV morphine sulfate (or Sponsor-approved equivalent), Standard of Care (SOC)
Experimental: Group 2
EXPAREL (bupivacaine liposome injectable suspension)
Related Therapeutic Areas
Sponsors
Collaborators: Registrat-Mapi
Leads: Pacira Pharmaceuticals, Inc

This content was sourced from clinicaltrials.gov

Similar Clinical Trials